Approaches to Treatment Resistance

Obsessive-Compulsive Disorder: Current Science and Clinical Practice

Volumn , Issue , 2012, Pages 99-131

  Pallanti, Stefano ^a,b,c   Grassi, Giacomo ^b   Cantisani, Andrea ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Institute for Neuroscience   (Italy)

Author keywords

Absence of best therapeutic in OCD, disorder homogeneity lacking; OCD terminological heterogeneity, compatibility with instruments scales; OCD treatment resistant one, patient and caregiver burden; OCD, and treatment resistance approaches; Resistant OCD, and pharmacological strategies; Switching, infusion, CBT, SRIs, antipsychotic, neurotransmitter glutamate; Treatment non response, from BD and ADHD in OCD; Treatment resistance, a feature of OCD; Y BOCS, (CGI) scale, HRQL

Indexed keywords

EID: 84886518202     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119941125.ch5     Document Type: Chapter

References (210)

1. CMI group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The clomipramine collaborative study group. Arch Gen Psychiatry 1991;48:730-738.
2. Goodman WK, Price LK. Assessment of severity and change in obsessive-compulsive disorder. Psychiatr Clin N Am 1992;15:861-869.
3. Jenike MA, Rauch SL. Managing the patients with treatment-resistant obsessive compulsive disorder: current strategies. J Clin Psychiatry 1994;55:11-17.
4. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive-compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin N Am 1993;15:749-766.
5. Piccinelli M, Pini S, Bellantonio C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995;166:242-243.
6. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-106.
7. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacological management of obsessive-compulsive disorder. J Clin Psichiatry 1993;54:4-9.
8. Pallanti S, Hollander E, Bienstock C et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191.
9. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:488-492.
10. Mataix-Cols D. Deconstructing obsessive-compulsive disorder: a multidimensional perspective. Curr Opin Psychiatry 2006;19:84-89.
11. Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA. Obsessivecompulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 1996;57(SUPPL. 8):3-6.
12. Dominguez RA, Mestre SM. Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry 1994;55:86-92.
13. Dominguez RA. Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. J Clin Psychiatry 1992;52:56-59.
14. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approach to treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 1993; 54(6 SUPPL.):16-26.
15. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004;65(SUPPL. 14):6-10.
16. Jefferson JW, Altemus M, Jenike MA, Pigott TA, Stein DJ, Greist JH. Algorithm for treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1995;31:487-490.
17. Jenike MA. Pharmacologic treatment of obsessive compulsive disorders. Psychiatr Clin N Am 1992;15:895-919.
18. March JS, Frances A, Kahn DA, Carpenter D. The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(SUPPL. 4):3-72.
19. Rasmussen S, Eisen JL. Treatment strategies for chronic and refractory obsessivecompulsive disorder. J Clin Psychiatry 1997;58(SUPPL. 13):9-13.
20. Goodman W, Price L, Rasmussen S et al. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
21. Goodman W, Price L, Rasmussen S et al. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part II: validity. Arch Gen Psychiatry 1989;46:1012-1016.
22. Goodman W, McDougle C, Price L. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry 1992;43:29-37.
23. Mavissalakian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? Am J Psychiatry 1985;142:572-576.
24. Apter A, Fallon T, KingR et al. Obsessive-compulsive characteristics: from symptoms to syndrome. J Am Acad Child Adolesc Psychiatry 1996;35:907-912.
25. Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale - Second Edition. Psychol Assess 2010;22:223-232.
26. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin N Am 2000;23:509-517.
27. Perugi G, Akiskal HS, Gemingnani A et al. Episodic course in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci 1998;248:240-244.
28. Ravizza L, Maina G, Bogetto F. Episodic and chronic obsessive-compulsive disorder. Depress Anxiety 1997;6:154-158.
29. Frank E, Prien R, Jarret R et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855.
30. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessivecompulsive disorder. J Clin Psychiatry 1997;58(SUPPL. 13):9-13.
31. Pato M, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptom after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-1525.
32. Pato MT, Hill JL, Murphy DL. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacol Bull 1990;26:211-214.
33. Leonard HL, Swedo SE, Lenane MC et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessivecompulsive disorder. Arch Gen Psychiatry 1991;48:922-927.
34. Mundo E, Bareggi S, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997;17:4-10.
35. Maina G, Albert U, Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:33-38.
36. Emsley RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 1999;60(SUPPL. 23):10-13.
37. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiat 2006;30:400-412.
38. Sheppard BA, Chavira D, Azzam A et al. ADHD prevalence and association with hoarding behaviors in childhood-onset OCD. Depress Anxiety 2010;27:667- 674.
39. Magalh{ogonek}aes PV, Kapczinski NS, Kapczinski F. Correlates and impact of obsessivecompulsive comorbidity in bipolar disorder. Compr Psychiatry 2010;51:353-356.
40. Goodman WK, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive compulsive disorder and related conditions. J Clin Psychiatry 1997;58(SUPPL. 5):32-49.
41. Rasmussen S, Baer L, Eisen J, Shera D. Previous SRI treatment and efficacy of sertraline for OCD: combined analysis of four multicenter trials. Poster presented at the 150th Annual Meeting of the American Psychiatry Association, San Diego, CA, 1997; pp. 17-22.
42. Ackerman D, Grennland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998;18:185-192.
43. Hollander E, Bienstock C, Koran L et al. Refractory obsessive compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 2002;63(SUPPL. 6):20-29.
44. Denys D, van Megen H, van der Wee N, Westenberg H. A double-blind switch study of paroxetine and venlafaxine in obsessive compulsive disorder. J Clin Psychiatry 2004;65:37-43.
45. Koran L, Aboujaoude E, Ward H et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive compulsive disorder. J Clin Psychopharmacol 2006;26:79-83.
46. Koran L, Hanna G, Hollander E et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007;164(7 SUPPL.):1-56.
47. Bogetto F, Maina G, Locatelli M, Lucca A. Terapie biologiche nel DOC. In: Smeraldi E (ed) Il Disturbo Ossessivo-Compulsivo e Il Suo Spettro, 3rd edn. Milan: Masson, 2003; pp. 336-366.
48. Marazziti D, Dell'Osso L, Gemignani A et al. Citalopram in refractory obsessivecompulsive disorder: an open study. Int Clin Psychopharmacol 2001;16:215-219.
49. Koran LM, Aboujaoude E, Bullok KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment resistant obsessive-compulsive disorder. J Clin Psychiatry 2005;66:353-359.
50. Dell'Osso B, Mundo E, Marazziti D, Altamura A. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 2008;22:210-213.
51. Pallanti S, Koran LM. La Cura del Paziente con Disturbo Ossessivo Compulsivo Resistente. Milan: Airon Edizione, 2003.
52. Fallon B, Liebowitz M, Campeas R et al. Intravenous clomipramine for obsessivecompulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998;55:918-924.
53. Koran L, Pallanti S, Quercioli L, Paiva R. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol 1998;8:121-126.
54. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002;63:796-801.
55. Ross S, Fallon BA, Petkova E, Feinstein S, Liebowitz MR. Long-term follow-up study of patients with refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2008;20:450-457.
56. Abramowitz JS. Does cognitive-behavioral therapy cure obsessive-compulsive disorder? A meta-analytic evaluation of clinical significance. Behav Ther 1998;29:339-355.
57. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011-1030.
58. Fisher PL, Wells A. How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. Behav Res Ther 2005;43:1543-1558.
59. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
60. Tundo A, Salvati L, Busto G, Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorders: a naturalistic study. J Clin Psychiatry 2007;68:1552-1556.
61. Simpson HB, Foa EB, Liebowitz MR. A randomized, controlled trial of cognitivebehavioral therapy for augmentation pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry 2008;165:621-630.
62. Storch E, Merlo L, Bengtson M et al. D-cycloserine does not enhance exposureresponse prevention therapy in obsessive-compulsive disorder. Int J Psychopharmacol 2007;22:230-237.
63. Kushner MG, Kim SW, Donahue C et al. D-cycloserine augmented exposure therapy for obsessive compulsive. Biol Psychiatry 2007;62:835-838.
64. Wilhelm S, Buhlmann U, Tolin D et al. Augmentation of behavior therapy with d-cycloserine for obsessive compulsive disorder. Am J Psychiatry 2008;165:335- 341.
65. Norberg M, Krystal J, Tolin D. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63:1118-1126.
66. Pallanti S, Quercioli L, Paiva R. Citalopram for treatment-resistant obsessivecompulsive disorder. Eur Psychiatry 1999;14:101-106.
67. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J Clin Psychiatry 1996;57:257-264.
68. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treatment of obsessivecompulsive disorder: long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-173.
69. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396- 401.
70. Simeon J, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990;26:285-290.
71. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A doubleblind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:11-18.
72. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10:165-169.
73. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double blind placebo-controlled study. J Clin Psychopharmacol 1998;13:219-224.
74. McDougle C, Price L, Goodman W, Charney D, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184.
75. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:420-430.
76. Choi YJ. Efficacy of treatment for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract 2009;21:207-213.
77. Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL.Adoubleblind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:156-162.
78. Bloom FE, Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998;23:653-659.
79. Dawes MA, Johnson BA, Ma JZ, Ait-Daoud N, Thomas SE, Cornelius JR. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 2005;30:1630-1637.
80. Costall B, Domeney AM, Naylor RJ, Tyers MB. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987;92:881-894.
81. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-5278.
82. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004;12:305-320.
83. Chamberlain SR, Menzies L, Hampshire A et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008;321:421-422.
84. HewlettWA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64:1025-1030.
85. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009;23:1047-1055.
86. Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. A doubleblind, placebo-controlled study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 2010;25:509-513.
87. Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004;65(SUPPL. 14): 11-17.
88. Pitman RK. Animal models of compulsive behavior. Biol Psychiatry 1989;26: 189-198.
89. Tizabi Y, Louis VA, Taylor CT, Waxman D, Culver KE, Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessivecompulsive disorder. Biol Psychiatry 2002;51:164-171.
90. Lochner C, Hemmings SM, Kinnear CJ et al. Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry 2005;46:14-19.
91. Pauls DL, Towbin KE, Leckman JF, Zahner GE, Cohen DJ. Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. Arch Gen Psychiatry 1986;43:1180-1182.92.
92. Pauls DL, Alsobrook II JP, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. Am J Psychiatry 1995;152:76-84.
93. Perani D, Garibotto V, Gorini A et al. In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug naive obsessive-compulsive disorder. Neuroimage 2008;42:306-314.
94. Westemberg HGM, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 2007;12:14-27.
95. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-632.
96. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003;6:397-401.
97. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxaminerefractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96:91-98.
98. McDougle CJ, Goodman WK, Price LH et al. Neuroleptic addition in fluvoxaminerefractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-654.
99. Matsunaga H, Nakata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long term trial of effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009;70:863- 868.
100. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308.
101. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitorrefractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794- 801.
102. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005;15:69-74.
103. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessivecompulsive disorder: a crossover study. J Clin Psychiatry 2005;66:736-743.
104. Pallanti S, Buchsbaum M, Hollander E. Neuroleptic augmentation in OCD: clinical and neuroimaging of risperidone. Presented at the 13th AEP Congress, Munich, 2-6 April, 2005.
105. Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitorrefractory obsessive-compulsive disorder: a single-blind, randomized study. Hum Psychopharmacol 2011;26:51-57.
106. Shapira NA, Ward HE, Mandoki M et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004;55:553-555.
107. Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004;65:565-568.
108. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 2008;18:364-372.
109. Denys D, De Geus F, Van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessivecompulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1040-1048.
110. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005;20:223-226.
111. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 2005;5:44.
112. Kordon A, Wahl K, Koch N et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2008;28:550-554.
113. Diniz JB, Shavitt RG, Pererira CA et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open label trial. J Psychopharmacol 2010;24:297-307.
114. Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411.
115. Da Rocha FF, Correa H. Successful augmentation with aripiprazole in clomipraminerefractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1550-1551.
116. Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2008;197:687-688.
117. Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessivecompulsive disorder. Depress Anxiety 2008;25:172-174.
118. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JRT. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatr 2005;66:49-51.
119. Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009;24:265-269.
120. Muscatello MR, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessivecompulsive disorder: a double-blind placebo-controlled study. J Clin Psychopharmacol 2011;31:174-179.
121. Iglesias Garcia C, Santamarina Montila S, AlonsoVilla MJ. Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment. Actas Esp Psiquiatr 2006;34:277-279.
122. McDougle CJ, Barr LC, Goodman WK et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-1814.
123. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:333-346.
124. Alevizos B, Papageorgiou C, Christodoulou GN. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 2004;7:375-377.
125. Diler RS, Yolga A, Avci A, Scahill L. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol 2003;13(SUPPL. 1):89-92.
126. Ke CL, Yen CF, Chen CC, Yang SJ, Chung W, Yang MJ. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci 2004;20:295-301.
127. Ozer S, Arsava M, Ertugrul A, Demir B. Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:724-727.
128. Stamouli S, Lykouras L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol 2006;26:396-400.
129. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-442.
130. de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent onset schizophrenia and other psychotic disorders. J Clin Psychiatry 1999;60:364-365.
131. Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci 2005;59:219-222.
132. Howland RH. Chlorpromazine and obsessive-compulsive symptoms. Am J Psychiatry 1996;153:1503.
133. Baker RW, Ames D, Umbricht DS et al. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull 1996;32:89-93.
134. Reznik I, Yavin I, Stryjer R et al. Clozapine in the treatment of obsessivecompulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 2004;37:52-56.
135. Ghaemi SN, Zarate CA Jr, Popli AP, Pillay SS, Cole JO. Is there a relationship between clozapine and obsessive compulsive disorder? A retrospective chart review. Compr Psychiatry 1995;36:267-270.
136. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001;26:55-59.
137. Tranulis C, Potvin S, Gourgue M, Leblanc G, Mancini-Marie A, Stip E. The paradox of quetiapine in obsessive-compulsive disorder. CNS Spectr 2005;10:356-361.
138. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476.
139. Kwon JS, Joo YH, Nam HJ et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 2009;66:1233-1241.
140. Insel TR, Hamilton JA, Guttmacher LB. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983;80:231-235.
141. Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:237-241.
142. Albucher RC Curtis CG. Adderall for obsessive-compulsive disorder. Am J Psychiatry 2001;158:818-819.
143. Owley T, Owley S, Leventhal B, Cook EH Jr. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2002;12:165-171.
144. Joffe RT, Swinson RP. Methylphenidate in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1987;7:420-422.
145. Van der Feltz-Cornelis CM. Intractable obsessive-compulsive disorder: comorbidity with unrecognized adult attention-deficit hyperactivity disorder? J Nerv Ment Dis 1999;187:243-245.
146. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009;70:1530-1535.
147. Arnsten AFT. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006;67:7-12.
148. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessivecompulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39:1096-1103.
149. Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in pediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol 2001;4:179-190.
150. Bolton J, Moore GJ, MacMillan S, Stewart CM, Rosenberg DR. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry 2001;40:903-906.
151. Moore GJ, MacMaster FP, Stewart C, Rosenberg DR. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998;37:663-667.
152. Carlsson ML. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 2000;102:401-413.
153. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30:1735-1740.
154. El Mansari M, Blier P. Mechanism of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:362-373.
155. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004;174:530-538.
156. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006;63:769-776.
157. Dickel DE, Veenstra-VanderWeele J, CoxNJ et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006;63:778-785.
158. Welch JM, Lu J, Rodriguiz RM et al. Cortico-striatal synaptic defects and OCD-like behavior in SAPAP3 mutant mice. Nature 2007;448:894-900.
159. Poyurovsky M, Weizman R, Weizman A, Koran L. Memantine for treatment-resistant OCD. Am J Psychiatry 2005;162:2191-2192.
160. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1173-1175.
161. Hezel DM, Beattie K, Stewart SE. Memantine as augmenting agent for severe pediatric OCD. Am J Psychiatry 2009;166:237.
162. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2009;29:51-55.
163. Stewart SE, Jenike EA, Hezel DM et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010;30:34-39.
164. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open label trial. Psychopharmacol Bull 2009;42:81-93.
165. Coric V, Taskiran S, Pittenger C et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58:424- 428.
166. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment resistant obsessive-compulsive disorder. J Clin Adolesc Psychopharmacol 2007;17:761-767.
167. Van Ameringen M, Mancini C, Patterson B, Bennet M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006;23:1-5.
168. Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2006;21:189-191.
169. Berlin HA, Koran ML, Jenike MA et al. Double-blind, placebo-controled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2010;72:716-721.
170. Lefleur DL, Pittenger C, KelmendiB et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184:254-256.
171. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008;18:455-461.
172. McDougle C, Barr L, Goodman W, Price L. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 1999;24:1-24.
173. Roy B, Benkelfalt C, Hill J et al. Serum antibody for somatostatin-14 and prodynorphine in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's desease, multiple sclerosis, and advanced HIV infection. Biol Psychiatry 1994;35:335-344.
174. Urraca N, Camarena B, Gomez-Caudillo L, Esmer MC, Nicolini H. Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am J Med Genet B Neuropsychiatr Genet 2004;127B:94-96.
175. Warneke L. A possible new treatment approach to obsessive compulsive disorder. Can J Psychiatry 1997;42; 667-668.
176. Shapira N, Keck P, Goldsmith T, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997;6:170-173.
177. Strassnig M, Riedel M, Miller N. Electroconvulsive therapy in a patient with Tourette's syndrome and co-morbid Obsessive Compulsive Disorder. World J Biol Psychiatry 2004;5:164-166.
178. Fukuschi T, Okada Y, Katayama H et al. [A case of pregnant woman with severe obsessive-compulsive disorder successfully treated by modified electroconvulsive therapy]. Seishin Shinkeigaku Zasshi 2003;105:927-932.
179. Hanish F, Friedmann J, Piro J, Gutmann P. Maintenance electroconvulsive therapy for comorbid pharmacotherapy-refractory obsessive-compulsive and schizoaffective disorder. Eur J Med Res 2009;14:367-368.
180. CaseyDA, Davis MH. Obsessive-compulsive disorder responsive to electroconvulsive therapy in an elderly woman. South Med J 1994;87:862-864.
181. Prasko J, Paskova B, Zalesky R et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. NeuroEndocrinol Lett 2006;27:327- 332.
182. Sachdev PS, Loo CK, Mitchell PB, McFarguhar TF, Malhi GS. Repetitive transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder: a doubleblind controlled investigation. Psychol Med 2007;37:1645-1649.
183. Alonso P, Pujol J, Cardoner N et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2001;158:1143-1145.
184. Ruffini C, Locatelli M, Lucca A, Benedetti F, Insacco C, Smeraldi E. Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. J Clin Psychiatry 2009;11:226-230.
185. Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH. Randomized shamcontrolled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 2010;13:217-227.
186. Baxter LR, Schwartz JM, Mazziotta JC et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1560-1563.
187. Rubin RT, Villanueva-Meyer J, Ananth J, Trajmar PG, Mena I. Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects: determination by high-resolution single-photon emission computed tomography. Arch Gen Psychiatry 1992;49:695-702.
188. Molina V, Montz R, Martin-Loeches M, Jimenez-Viciozo A, Carreras JL, Rubia FJ. Drug therapy and cerebral perfusion in obsessive-compulsive disorder. J Nucl Med 1995;36:2234-2238.
189. Alptekin K, Degermenci B, Kivircik B et al. Tc-99m HMPAO brain perfusion SPECT in drug-free obsessive-compulsive patients without depression. Psychiatry Res 2001;107:51-56.
190. Y'ucel M, Harrison BJ, Wood SJ et al. Functional and biochemical alterations of the medial frontal cortex in OCD. Arch Gen Psychiatry 2007;64:946-955.
191. Greenberg BD, Ziemann U, Harmon A, Murphy DL, Wassermann EM. Decreased neuronal inhibition in cerebral cortex in obsessive-compulsive disorder on transcranial magnetic stimulation. Lancet 1998;352:881-882.
192. Greenberg BD, Ziemann U, Cora-Locatelli G et al. Altered cortical excitability in obsessive-compulsive disorder. Neurology 2000;54:142-147.
193. Shah DB, Pesiridou A, Baltuch GH, Malone DA, O'Reardon JP. Functional neurosurgery in the treatment of severe obsessive compulsive disorder and major depression: overviewof disease circuits and therapeutic targeting for the clinician. Psychiatry (Edgmont) 2008;5:24-33.
194. Abelson JL, Curtis GC, Sagher O et al. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 2005;57:510-516.
195. Anderson D, Ahmed A. Treatment of patients with intractable obsessivecompulsive disorder with anterior capsular stimulation. Case report. J Neurosurg 2003;98:1104-1108.
196. Gabriels L, Cosyns P, Nuttin B, Demeulemeester H, Gybels J. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 2003;107:275-282.
197. Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet 1999;354:1526.
198. Nuttin BJ, Gabriels LA, Cosyns PR et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2003;52:1263-1272.
199. Nuttin BJ, Gabriels LA, Cosyns PR et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2008;62:966-977.
200. Greenberg BD, Malone DA, Friehs GM et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006;31:2384-2393.
201. Figee M, Vink M, de Geus F et al. Dysfunctional reward circuitry in obsessivecompulsive disorder. Biol Psychiatry 2011 May 1;69(9):867-874. Epub 2011 Jan 26.
202. Sturm V, Lenartz D, Koulousakis A et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive and anxiety disorders. J Chem Neuroanat 2003;26:293-299.
203. Denys D, Mantione M, Figee M et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2010;67:1061-1068.
204. Huff W, Lenarz D, Schormann M et al. Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: outcomes after one year. Clin Neurol Neurosurg 2010;112:137-143.
205. Aouizerate B, Cuny E, Martin-Guehl C et al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 2004;101:682-686.
206. Mallet L, Polosan M, Jaafari N et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008;359:2121-2134.
207. Jimenez F, Velasco F, Salin-Pascual R et al. Neuromodulation of the inferior thalamic peduncle for major depression and obsessive compulsive disorder. Acta Neurochir SUPPL 2007;97:393-398.
208. Karla H, Kamath P, Trivedi JK, Janca A. Caregiver burden in anxiety disorders. Curr Opin Psychiatry 2008;21:70-73.
209. Hoenig K, Hochrein A, Quednow BB, Maier W, Wagner M. Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biol Psychiatry 2005;57:1153-1158.
210. Harmer CJ, Reid CB, Ray MK, Goodwin GM, Cowen PJ. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology (Berl) 2006;186:18-24.